BOSTON, June 18 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global bio/pharmaceutical services organization, today announced that it has opened a new location in Hyderabad, India. Through this new location, PAREXEL offers its clients a wide range of clinical research and data management services while deepening its long-term commitment in India.
“We are especially excited to be breaking ground in India’s 6th largest metropolis, which is quickly becoming an important biotechnology hub,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “With the addition of Hyderabad, PAREXEL provides biopharmaceutical and medical device companies with greater access to strength of our expertise, experience and innovation to help expedite getting their products to market faster.”
PAREXEL’s Hyderabad office is staffed by locally-based key management, and a team of highly skilled experts with extensive knowledge of India’s regulatory process. Clients can also benefit from PAREXEL’s existing alliances with regional academic institutions, strategic access to key investigator sites and established relationships with regulatory authorities.
“Last year, PAREXEL entered into a joint venture arrangement with Synchron, an India-based clinical research organization, to form PAREXEL International Synchron Private Limited, to provide a broad range of Phase II- IV clinical research services,” said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics, PAREXEL International. “The opening of PAREXEL’s Hyderabad location was a natural next step to meet client demand in India for our services.”
For more information about PAREXEL, visit www.PAREXEL.com or visit Booth #724 at the DIA’s 43rd Annual Meeting.
About the Company
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 57 locations throughout 43 countries around the world, and has over 6,315 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2007 as filed with the SEC on May 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Contacts: Karen Wills, Vice President Corporate Marketing PAREXEL International Tel: +781-434-5301 Email: karen.wills@PAREXEL.com Rebecca Passo SHIFT Communications Tel: +617-779-1817 Email: rpasso@shiftcomm.com
PAREXEL International Corporation
CONTACT: Karen Wills, Vice President Corporate Marketing of PAREXELInternational Corporation, +1-781-434-5301, karen.wills@PAREXEL.com; orRebecca Passo of SHIFT Communications, +1-617-779-1817,rpasso@shiftcomm.com
Web site: http://www.parexel.com/
